Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...
City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...
Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & ...
Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay ...
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...
IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...
As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...
A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 ...
Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
Sutro scale-up, Pharma mergers, FDA warnings to Indian firms, new Egypt facility, and UPS acquires Frigo-Trans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback